On August 13, 2024, Exicure, Inc., a biotechnology company based in Chicago, reported its financial results for the second quarter ended June 30, 2024. The company, which has been focusing on nucleic acid therapies, announced a significant reduction in force and suspension of preclinical activities in September 2022, and is currently exploring strategic alternatives to maximize shareholder value. Exicure's cash and cash equivalents stood at $0.5 million, down from $0.8 million at the end of 2023, indicating a need for immediate additional funding to continue operations. General and administrative expenses decreased to $1.2 million for the quarter, down from $5.6 million in the same period last year, primarily due to reduced payroll and operating costs. The company also reported other income of $0.6 million from the sale of clinical product samples. Despite cost reductions, Exicure incurred a net loss of $0.6 million for the quarter, an improvement from a net loss of $5.8 million in the previous year. The company's management has expressed concern about the sufficiency of its cash reserves to fund ongoing operations and the urgent need for additional financing.

On August 13, 2024, Exicure, Inc., a biotechnology company based in Chicago, reported its financial results for the second quarter ended June 30, 2024. The company, which has been focusing on nucleic acid therapies, announced a significant reduction in force and suspension of preclinical activities in September 2022, and is currently exploring strategic alternatives to maximize shareholder value. Exicure's cash and cash equivalents stood at $0.5 million, down from $0.8 million at the end of 2023, indicating a need for immediate additional funding to continue operations. General and administrative expenses decreased to $1.2 million for the quarter, down from $5.6 million in the same period last year, primarily due to reduced payroll and operating costs. The company also reported other income of $0.6 million from the sale of clinical product samples. Despite cost reductions, Exicure incurred a net loss of $0.6 million for the quarter, an improvement from a net loss of $5.8 million in the previous year. The company's management has expressed concern about the sufficiency of its cash reserves to fund ongoing operations and the urgent need for additional financing.